TrialThe Lancet. Oncology2023

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Eric Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.